CTOs on the Move

Wisq

www.wisq.com

 
Wisq is a space for life at work. The Wisq platform helps employees improve social well-being by enabling them to connect, share and build relationships at work. Organizations increase employee engagement, improve belonging and retention and build happy work cultures. Wisq enables smart profiles, intuitive sharing, community building and audio lounges for informal hangouts. Based in Redwood City, CA, the company was founded by three former Glint executives: Jim Barnett, chief executive officer; Goutham Kurra, chief product officer; and Chih-Po Wen, chief technology officer. Wisq has raised more than $40 million and is backed by True Ventures, Norwest Venture Partners ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.wisq.com
  • 835 Main Street
    Redwood City, CA USA 94063
  • Phone: n/a

Executives

Name Title Contact Details

Similar Companies

Digite

Digité provides Artificial Intelligence driven project delivery management solutions based on Agile, Kanban & SAFe® - Scaled Agile Framework.

Graphisme Alpha Vision Ml Inc

Graphisme Alpha Vision Ml Inc is a Laval, QC-based company in the Software and Internet sector.

TurnKey GNU/Linux

TurnKey Linux is a library of free Debian-based system images that integrate and polish the best open source software into ready-to-use solutions. Each virtual appliance is optimized for ease of use and can be deployed in just a few minutes on bare met...

FLOWX.AI

FLOWX.AI is a no-code software platform that helps financial institutions build digital apps quickly and easily. Their platform allows for the development of omnichannel apps in days, not months, and their AI-driven UI generator and ZeroRedeploy techno...

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.